[{"id":"7ae66fef-a243-4d8f-b364-a73eb3507cdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633122","created_at":"2021-01-19T20:36:54.322Z","updated_at":"2025-02-25T15:34:48.949Z","phase":"Phase 2","brief_title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","source_id_and_acronym":"NCT04633122","lead_sponsor":"Zai Lab (Shanghai) Co., Ltd.","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Qinlock (ripretinib)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 11/25/2020","start_date":" 11/25/2020","primary_txt":" Primary completion: 07/20/2022","primary_completion_date":" 07/20/2022","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2025-02-10"},{"id":"ddcdaa98-710f-4836-a6b4-89e5e80022ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05957367","created_at":"2023-07-24T15:08:40.775Z","updated_at":"2024-07-02T16:34:59.920Z","phase":"Phase 1/2","brief_title":"A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies","source_id_and_acronym":"NCT05957367","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" BRAF • KIT • PDGFRA","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation","tags":["BRAF • KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • Qinlock (ripretinib) • inlexisertib (DCC-3116)"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-31"},{"id":"bf439f30-e0dc-43f8-a4c4-f4b1f0fa3a26","acronym":"","url":"https://clinicaltrials.gov/study/NCT02571036","created_at":"2021-01-17T17:36:28.986Z","updated_at":"2024-07-02T16:35:26.428Z","phase":"Phase 1","brief_title":"A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT02571036","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation • KIT amplification","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation • KIT amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qinlock (ripretinib)"],"overall_status":"Completed","enrollment":" Enrollment 282","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 04/29/2022","primary_completion_date":" 04/29/2022","study_txt":" Completion: 04/29/2022","study_completion_date":" 04/29/2022","last_update_posted":"2023-12-13"},{"id":"85d16f1e-1c34-4a39-a9c5-34455f313731","acronym":"","url":"https://clinicaltrials.gov/study/NCT05132738","created_at":"2021-11-24T18:55:38.113Z","updated_at":"2024-07-02T16:36:20.274Z","phase":"","brief_title":"Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy","source_id_and_acronym":"NCT05132738","lead_sponsor":"RenJi Hospital","biomarkers":" KIT • ANO1","pipe":"","alterations":" ","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Qinlock (ripretinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2021-11-24"}]